Avalyn Pharma Inc. Common Stock
AVLN | NASDAQ
$25.63
-$0.08 (-0.31%)
At close: Oct 30, 2026, 4:00 PM ET
$23.20
-$2.43 (-9.48%)
Pre-market:
Nov 2, 2026, 6:23 AM ET
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Net Income | -55.8M | -26.87M |
Depreciation & Amortization | 173K | 63K |
Stock-Based Compensation | 1.19M | 1.19M |
Other Working Capital | -2.94M | -3.04M |
Other Non-Cash Items | 2.62M | -123K |
Deferred Income Tax | n/a | n/a |
Change in Working Capital | -4.15M | -4.16M |
Operating Cash Flow | -55.97M | -29.89M |
Capital Expenditures | -587K | -318K |
Cash Acquisitions | n/a | n/a |
Purchase of Investments | -134.83M | n/a |
Sales Maturities Of Investments | 71.73M | 55.34M |
Other Investing Acitivies | n/a | n/a |
Investing Cash Flow | -63.69M | 55.02M |
Debt Repayment | 14.79M | 15M |
Common Stock Repurchased | n/a | n/a |
Dividend Paid | n/a | n/a |
Other Financial Acitivies | -163K | -163K |
Financial Cash Flow | 331.54M | 14.86M |
Net Cash Flow | 211.88M | 40M |
Free Cash Flow | -56.55M | -30.21M |
Adj. Free Cash Flow | -57.75M | -31.4M |
Maintenance CapEx | n/a | n/a |
Growth CapEx | n/a | n/a |
Owner Earnings | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove AVLN